MedTrace Logo

Vaginal Versus Combined Use of Progesterone in Fresh IVF/ICSI Cycles

NCT05089383 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 698

Last updated 2021-10-22

No results posted yet for this study

Summary

Hypothesis: the combined use of progesterone administration for luteal phase support is superior to the single route of progesterone administration in terms of pregnancy outcome parameters in women undergoing fresh IVF/ICSI cycles.

Conditions

  • Luteal Phase

Interventions

DRUG

Utrogestan

PROSPECTIVE STUDY

Sponsors & Collaborators

  • Iaso Maternity Hospital, Athens, Greece

    collaborator OTHER

  • University of Athens

    lead OTHER

Principal Investigators

  • Nikolaos Vlachos · National and Kapodistrian University of Athens

Eligibility

Min Age
22 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-14
Primary Completion
2023-02-28
Completion
2023-12-31
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05089383 on ClinicalTrials.gov